257 related articles for article (PubMed ID: 28035063)
1. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
4. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.
Haruyama Y; Yorita K; Yamaguchi T; Kitajima S; Amano J; Ohtomo T; Ohno A; Kondo K; Kataoka H
Int J Cancer; 2015 Oct; 137(7):1643-51. PubMed ID: 25784484
[TBL] [Abstract][Full Text] [Related]
5. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
6. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation.
Wang YL; Zhu ZJ; Teng DH; Yao Z; Gao W; Shen ZY
World J Gastroenterol; 2012 May; 18(19):2408-14. PubMed ID: 22654434
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
11. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
12. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy.
Chen IP; Ariizumi S; Nakano M; Yamamoto M
J Gastroenterol; 2014 Jan; 49(1):117-25. PubMed ID: 23532638
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients.
Ning S; Bin C; Na H; Peng S; Yi D; Xiang-hua Y; Fang-yin Z; Da-yong Z; Rong-cheng L
Mol Biol Rep; 2012 Jan; 39(1):351-7. PubMed ID: 21655958
[TBL] [Abstract][Full Text] [Related]
14. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
[TBL] [Abstract][Full Text] [Related]
15. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
[TBL] [Abstract][Full Text] [Related]
16. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.
Shimizu Y; Mizuno S; Fujinami N; Suzuki T; Saito K; Konishi M; Takahashi S; Gotohda N; Tada T; Toyoda H; Kumada T; Miura M; Suto K; Yamaji T; Matsuda T; Endo I; Nakatsura T
Cancer Sci; 2020 Feb; 111(2):334-342. PubMed ID: 31774932
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
18. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
20. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
